Daily MedNews
Printable Version   Email to a friend

Health Highlights: Aug. 19, 2008

Here are some of the latest health and medical news developments, compiled by editors of HealthDay:

Vioxx Study Was 'Stealth' Marketing: Report

Stealth marketing was the main goal of a 1999 Vioxx study touted by Merck & Co. as proof that the painkiller caused fewer stomach problems than a less expensive painkiller called naproxen, according to a report published Tuesday in the journal Annals of Internal Medicine.

The actual purpose of the ADVANTAGE study wasn't scientific, but rather to get doctors and patients in the habit of using Vioxx just in time for its launch, according to the report authors, who uncovered internal Merck documents, the Associated Press said.

The documents revealed that Merck's marketing division designed ADVANTAGE and handled the study's data collection and analysis, the news service said.

It's long been suspected that drug companies regularly do such marketing-oriented studies, but there's never been a "smoking gun" proving it, the report authors noted.

The Annals of Internal Medicine published the ADVANTAGE study in 2003 but was not told the true purpose of the study, according to an accompanying editorial co-authored by journal editior Dr. Harold C. Sox, the AP reported.

Vioxx was pulled from the market in 2004 after it was linked to cardiovascular problems.

-----

Bad Peppers a Problem Before Salmonella Outbreak

In the months before a salmonella outbreak caused by Mexican chilies sickened 1,400 people in the United States this year, inspectors at U.S. border crossings repeatedly turned back shipments of unhealthy peppers, according to an Associated Press analysis of Food and Drug Administration documents.

Despite the repeated problems with Mexican peppers, no larger action was taken to protect American consumers, the news services said.

Since January, 88 shipments of fresh and dried chilies from Mexico were turned away by U.S. border inspectors. Ten percent of those shipments were contaminated with salmonella. Within the last year, eight percent of the 158 intercepted shipments of fresh and dried chilies from Mexico were contaminated with salmonella, the AP reported.

Food safety advocates want to know why the FDA didn't pay closer attention to the peppers being turned away at the border, and why the agency's screening of companies known for shipping dirty chilies only increased after the salmonella outbreak.

As recently as last week, FDA officials insisted they were surprised by the salmonella outbreak because Mexican peppers had not been spotted as a problem before the outbreak, the AP reported.

-----

More 40-Something U.S. Women Are Childless

Fewer American women in their 40s have children, according to a Census Bureau study that examined data from a 2006 survey of 76 million women, ages 15 to 50. About 4.2 million of the women had had a child in the previous year.

The study found that in the last 30 years, the number of women ages 40 to 44 with no children has increased from 10 percent to 20 percent. Those who were mothers in 2006 had an average of 1.9 children each, more than one child fewer than women ages 40 to 44 had in 1976, the Associated Press reported.

In 2006, women with graduate or professional degrees had the most births of women in all educational levels. The study, Fertility of American Women: 2006, also found that about 36 percent of women who gave birth in the previous year were separated, divorced, widowed or unmarried.

While unemployed women had about twice as many babies as working women, those who had jobs accounted for 57 percent of recent births. Among women who had a child during the previous year, about one-quarter were living below the poverty line, the AP reported.

-----

Lower Drinking Age to 18: College Presidents

More than 100 American college presidents want the drinking age lowered from 21 to 18 in an effort to reduce binge drinking by students.

"Twenty-one is not working," the presidents declared in a signed statement. "A culture of dangerous, clandestine 'binge-drinking' -- often conducted off-campus -- has developed," the Long Island, N.Y., newspaper Newsday reported.

In a separate statement, Duke University President Richard Brodhead said the current legal drinking age of 21 "pushes drinking into hiding, heightening its risks, including risks from drunken driving, and it prevents us from addressing drinking with students as an issue of responsible choice."

But the college presidents' campaign, which may include newspaper ads in the coming weeks, faces sharp criticism from Mothers Against Drunk Driving. The group accused the presidents of misrepresenting research and urged parents to carefully consider the safety of their children at colleges whose presidents are seeking to lower the drinking age.

Laura Dean-Mooney, national president of MADD, suggested that the current drinking age will not be enforced at those colleges, Newsday reported.

-----

2 Deaths Reported Among Users of Byetta, a Diabetes Drug

Two deaths have resulted from six recent cases of pancreatitis among users of the diabetes drug Byetta, marketed by drug makers Amylin Pharmaceuticals and Eli Lilly & Co., the U.S. Food and Drug Administration said Monday.

The other four pancreatitis patients are recovering, the Associated Press reported. The FDA is working on stronger labeling for the drug after the recent deaths, which came despite earlier government warnings about users' increased risk of acute pancreatitis, an inflammation of the pancreas.

The injected drug is marketed for people with type 2 diabetes. It has been used by more than 700,000 people since being approved in June 2005, the AP said.

The drug companies issued a statement warning that among people taking Byetta there are "very rare case reports of pancreatitis with complications or with a fatal outcome." Diabetics are already at greater-than-normal risk of pancreatitis, the companies said.

Monday's FDA announcement was preceded last October by its warning that there had been 30 reports of pancreatitis among Byetta users. In that announcement, the FDA warned that people should stop taking the drug if they developed symptoms of acute pancreatitis, including nausea and abdominal pain.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 24, 2008
Audience: Neurological healthcare professionals[Posted 11/24/2008] FDA is investigating new preliminary data regarding a...
November 20, 2008
Audience: Consumers, endocrinological healthcare professionals [Posted 11/20/2008] Animas Corporation and FDA informed consumers...
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
More...
Latest Drug Information Updates

Promacta
Promacta (eltrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.

Banzel
Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

More...